Exec Tells DAILY: Shire Wants FDA Meeting Before Phase III Fosrenol Trial in Pre-Dialysis CKD Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from Phase II study could put Genzyme’s competing Renvela at an advantage, though Shire used a more aggressive endpoint.